Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

APO2 ligand: a novel lethal weapon against malignant glioma?

Rieger, Johannes, Naumann, Ulrike, Glaser, Tamara, Ashkenazi, Avi, Weller, Michael · 1998 · FEBS Letters

Abstract

APO2L (TRAIL) is a novel CD95L (Fas/APO‐1‐L) homologous cytotoxic cytokine that interacts with various receptors which transmit (DR4, DR5) or inhibit (DcR1, DcR2) an apoptotic signal. Here, we report that human glioma cell lines preferentially express mRNAs for agonistic death receptors DR4 (8/12) and DR5 (11/12) rather than the death‐inhibitory decoy receptors DcR1 (4/12) and DcR2 (2/12). Ten of 12 cell lines are susceptible to APO2L‐induced apoptosis. The resistant cell lines, U138MG and U373MG, are cross‐resistant to CD95L‐induced apoptosis. Similar to CD95L‐induced apoptosis, APO2L‐induced apoptosis is inhibited by ectopic expression of the caspase inhibitor, crm‐A, or of bcl‐2, or by coexposure to the corticosteroid, dexamethasone, or the lipoxygenase inhibitor, nordihydroguaretic acid. There is no correlation between p53 genetic status of the cell lines and their susceptibility to APO2L‐induced apoptosis, but the latter is moderately enhanced by ectopic expression of wild‐type p53. APO2L targeting may be a promising approach for selectively targeting apoptosis to human malignant glioma cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0014-5793(98)00409-8

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 189

Metadata

Authors
Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., & Weller, M.
Venue
FEBS Letters
Publisher
Wiley
Published
1998-05
Volume
427
Issue
1
Pages
124-128
ISSN
  • 0014-5793 (ISSN-L)
  • 1873-3468
OpenAlex
W2055905844
Cited by
189
References
2
FWCI
6.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: APO2 ligand: a novel lethal weapon against malignant glioma? https://app.cochat.ai/papers/10.1016/s0014-5793(98)00409-8
The paper
Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., & Weller, M. (1998). APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Letters. https://doi.org/10.1016/s0014-5793(98)00409-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.